LGND241220C140000
- 2.05
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Selling US$6.3m Of Stock Was Lucrative Decision For Ligand Pharmaceuticals Insiders
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $150
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings
Ligand to Present at Stifel 2024 Healthcare Conference
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 3.87 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNZZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$Ligand
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $140
A Quick Look at Today's Ratings for Ligand Pharmaceuticals(LGND.US), With a Forecast Between $135 to $150
Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
10-Q: Q3 2024 Earnings Report
Ligand Pharmaceuticals Analyst Ratings
Ligand Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Ligand Pharmaceuticals Incorporated (LGND) Q3 2024 Earnings Call Transcript Summary
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $150
Sector Update: Health Care Stocks Rise Late Afternoon
Ligand Shares Rise After Q3 Tops Expectations, Guidance Raised
Ligand Pharmaceuticals Boosts FY24 Outlook - Update
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q3 Revenue $51.8M
Ligand Pharmaceuticals Inc Q3 Earnings Summary
8-K: Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance